Ayvakit (avapritinib) Tablets
Date of Approval: January 9, 2020
Company: Blueprint Medicines Corporation
Treatment for: Gastrointestinal Stromal Tumor
Ayvakit (avapritinib) is a kinase inhibitor for the treatment of PDGFRα exon 18 mutant gastrointestinal stromal tumors (GIST).
FDA Approves Ayvakit (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
Valtoco (diazepam) Nasal Spray
Date of Approval: January 10, 2020
Company: Neurelis, Inc.
Treatment for: Epilepsy
Valtoco (diazepam) is a benzodiazepine nasal spray for the short-term treatment of epilepsy cluster seizures.
FDA Approves Valtoco (diazepam nasal spray) as a Seizure Rescue Treatment
Numbrino (cocaine hydrochloride) Nasal Solution
Date of Approval: January 10, 2020
Company: Lannett Company, Inc.
Treatment for: Nasal Anesthesia
Numbrino (cocaine hydrochloride) nasal solution is a local anesthetic indicated for the introduction of local anesthesia of the mucous membranes for diagnostic procedures and surgeries on or through the nasal cavities of adults.
FDA Approves Numbrino (cocaine hydrochloride) Nasal Solution for Nasal Anesthesia
Tepezza (teprotumumab-trbw) Injection
Date of Approval: January 21, 2020
Company: Horizon Therapeutics plc
Treatment for: Thyroid Eye Disease
Tepezza (teprotumumab-trbw) is a fully human monoclonal antibody (mAb) and a targeted inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) for the treatment of active thyroid eye disease (TED).
FDA Approves Tepezza (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED)
Tazverik (tazemetostat) Tablets
Date of Approval: January 23, 2020
Company: Epizyme, Inc.
Treatment for: Epithelioid Sarcoma
Tazverik (tazemetostat) is a methyltransferase inhibitor for the treatment of patients with epithelioid sarcoma.
FDA Approves Tazverik (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma
Trijardy XR (empagliflozin, linagliptin and metformin hydrochloride) Extended-Release Tablets
Date of Approval: January 27, 2020
Company: Boehringer Ingelheim and Eli Lilly and Company
Treatment for: Diabetes Type 2
Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride) is a fixed-dose combination of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance), the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin (Tradjenta) and the biguanide metformin hydrochloride indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
FDA Approves Trijardy XR (empagliflozin/linagliptin/metformin) for Type 2 Diabetes in Adults
Monoferric (ferric derisomaltose) Injection
Date of Approval: January 16, 2020
Company: Pharmacosmos Therapeutics Inc.
Treatment for: Iron Deficiency Anemia
Monoferric (ferric derisomaltose) is an intravenous iron replacement product indicated for the treatment of iron deficiency anemia.
FDA Approves Monoferric (ferric derisomaltose) Injection for the Treatment of Iron Deficiency Anemia
Palforzia (Peanut (Arachis hypogaea) Allergen Powder-dnfp) - formerly AR101
Date of Approval: January 31, 2020
Company: Aimmune Therapeutics, Inc.
Treatment for: Peanut Allergy
Palforzia (Peanut (Arachis hypogaea) Allergen Powder-dnfp) is an oral immunotherapy indicated to help reduce the severity of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut.
FDA Approves Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] as First Treatment for Peanut Allergy
Audenz (influenza A (H5N1) monovalent vaccine, adjuvanted) Injection
Date of Approval: January 31, 2020
Company: Seqirus
Treatment for: Influenza Prophylaxis
Audenz (influenza A (H5N1) monovalent vaccine, adjuvanted) is a cell-based influenza vaccine designed to protect against influenza A (H5N1) in the event of a pandemic.
FDA Approves Audenz (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) as First-Ever Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine
Pemfexy (pemetrexed) Injection
Date of Approval: February 8, 2020
Company: Eagle Pharmaceuticals, Inc.
Treatment for: Non-Small Cell Lung Cancer, Malignant Pleural Mesothelioma
Pemfexy (pemetrexed for injection) is a branded alternative to Alimta for the treatment of nonsquamous non-small cell lung cancer and malignant pleural mesothelioma.
FDA Approves Pemfexy (pemetrexed for injection) as a Branded Alternative to Alimta
Pizensy (lactitol) Powder for Oral Solution
Date of Approval: February 12, 2020
Company: Braintree Laboratories, Inc.
Treatment for: Chronic Idiopathic Constipation
Pizensy (lactitol) is an osmotic laxative indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
FDA Approves Pizensy (lactitol) for the Treatment of Chronic Idiopathic Constipation (CIC)
Twirla (ethinyl estradiol and levonorgestrel) Transdermal System
Date of Approval: February 14, 2020
Company: Agile Therapeutics, Inc.
Treatment for: Contraception
Twirla (ethinyl estradiol and levonorgestrel transdermal system) is a low-dose combined hormonal contraceptive patch for birth control.
FDA Approves Twirla (levonorgestrel and ethinyl estradiol) Contraceptive Patch
Anjeso (meloxicam) Injection
Date of Approval: February 20, 2020
Company: Baudax Bio, Inc.
Treatment for: Pain
Anjeso (meloxicam) is a non-steroidal anti-inflammatory drug (NSAID) injection indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics.
FDA Approves Anjeso (meloxicam injection) for the Management of Moderate to Severe Pain
Nexletol (bempedoic acid) Tablets
Date of Approval: February 21, 2020
Company: Esperion Therapeutics, Inc.
Treatment for: Heterozygous Familial Hypercholesterolemia
Nexletol (bempedoic acid) is a first-in-class, adenosine triphosphate-citrate lyase (ACL) inhibitor for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-Cholesterol.
FDA Approves Nexletol (bempedoic acid) to Lower LDL-Cholesterol
Vyepti (eptinezumab-jjmr) Injection
Date of Approval: February 21, 2020
Company: Lundbeck
Treatment for: Migraine Prophylaxis
Vyepti (eptinezumab-jjmr) is a calcitonin gene-related peptide antagonist indicated for the prevention of migraine in adults.
FDA Approves Vyepti (eptinezumab-jjmr) Intravenous Injection for the Preventive Treatment of Migraine
Nexlizet (bempedoic acid and ezetimibe) Tablets
Date of Approval: February 26, 2020
Company: Esperion Therapeutics
Treatment for: Heterozygous Familial Hypercholesterolemia
Nexlizet (bempedoic acid and ezetimibe) is an adenosine triphosphate-citrate lyase (ACL) inhibitor and a cholesterol absorption inhibitor combination indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
FDA Approves Nexlizet (bempedoic acid and ezetimibe) to Lower LDL-Cholesterol
Barhemsys (amisulpride) Injection
Date of Approval: February 26, 2020
Company: Acacia Pharma
Treatment for: Nausea/Vomiting -- Postoperative
Barhemsys (amisulpride) is a dopamine-2 (D2) antagonist for the management of post-operative nausea and vomiting (PONV).
FDA Approves Barhemsys (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting
Nurtec ODT (rimegepant) Orally Disintegrating Tablets (ODT)
Date of Approval: February 27, 2020
Company: Biohaven Pharmaceutical Holding Company Ltd.
Treatment for: Migraine
Nurtec ODT (rimegepant) is an orally-dosed calcitonin gene-related peptide (CGRP) receptor antagonist for the acute treatment of migraine.
FDA Approves Nurtec ODT (rimegepant) for the Acute Treatment of Migraine in Adults
Advil Dual Action (ibuprofen and acetaminophen) Tablets
Date of Approval: February 28, 2020
Company: GSK Consumer Healthcare
Treatment for: Pain
Advil Dual Action (ibuprofen with acetaminophen) is an over-the-counter (OTC) fixed-dose combination of ibuprofen (the nonsteroidal anti-inflammatory drug (NSAID) contained in Advil) and acetaminophen (the active ingredient in Tylenol) for the relief of pain.
FDA Approves Advil Dual Action (ibuprofen and acetaminophen) as an Over-the-Counter Pain Treatment
Pizensy (lactitol) Powder for Oral Solution
Date of Approval: February 12, 2020
Company: Braintree Laboratories, Inc.
Treatment for: Chronic Idiopathic Constipation
Pizensy (lactitol) is an osmotic laxative indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
FDA Approves Pizensy (lactitol) for the Treatment of Chronic Idiopathic Constipation in Adults
Sarclisa (isatuximab-irfc) Injection
Date of Approval: March 2, 2020
Company: Sanofi
Treatment for: Multiple Myeloma
Sarclisa (isatuximab-irfc) is a CD38-directed cytolytic antibody indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients multiple myeloma.
FDA Approves Sarclisa (isatuximab-irfc) for Patients with Relapsed Refractory Multiple Myeloma
Durysta (bimatoprost) Implant
Date of Approval: March 3, 2020
Company: Allergan plc
Treatment for: Glaucoma (Open Angle), Intraocular Hypertension
Durysta (bimatoprost implant) is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).
FDA Approves Durysta (bimatoprost implant) to Lower Intraocular Pressure In Open-Angle Glaucoma or Ocular Hypertension Patients
Isturisa (osilodrostat) Tablets
Date of Approval: March 6, 2020
Company: Novartis Pharmaceuticals Corporation
Treatment for: Cushing's Syndrome
Isturisa (osilodrostat) is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing’s disease.
FDA Approves Isturisa (osilodrostat) for the Treatment of Cushing’s Disease
Zeposia (ozanimod) Capsules
Date of Approval: March 25, 2020
Company: Bristol-Myers Squibb Company
Treatment for: Multiple Sclerosis
Zeposia (ozanimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS).
FDA Approves Zeposia (ozanimod) for Relapsing Forms of Multiple Sclerosis
Sevenfact (coagulation factor VIIa (recombinant)-jncw) Injection
Date of Approval: April 1, 2020
Company: HEMA Biologics, LLC
Treatment for: Hemophilia A or B with Inhibitors
Sevenfact (coagulation factor VIIa [recombinant]-jncw) is a coagulation factor VIIa concentrate indicated for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors (neutralizing antibodies).
FDA Approves Sevenfact [coagulation factor VIIa (recombinant)-jncw] for Treatment and Control of Bleeding Episodes Occurring in Adult and Adolescent Hemophilia A and B Patients with Inhibitors
Koselugo (selumetinib) Capsules
Date of Approval: April 10, 2020
Company: AstraZeneca and Merck
Treatment for: Neurofibromatosis Type 1
Koselugo (selumetinib) is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2) indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
FDA Approves Koselugo (selumetinib) for Pediatric Patients with Neurofibromatosis Type 1 Plexiform Neurofibromas
Jelmyto (mitomycin) for Pyelocalyceal Solution
Date of Approval: April 15, 2020
Company: UroGen Pharma Ltd.
Treatment for: Urothelial Carcinoma
Jelmyto (mitomycin) is a novel formulation of the approved alkylating drug mitomycin for the treatment of patients with low-grade upper tract urothelial cancer (LG-UTUC).
FDA Approves Jelmyto (mitomycin) for Treatment of Low-Grade Upper Tract Urothelial Cancer
Tukysa (tucatinib) Tablets
Date of Approval: April 17, 2020
Company: Seattle Genetics, Inc.
Treatment for: Breast Cancer
Tukysa (tucatinib) is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for the treatment of patients with advanced unresectable or metastatic HER2-positive breast cancer.
FDA Approves Tukysa (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer
Pemazyre (pemigatinib) Tablets
Date of Approval: April 17, 2020
Company: Incyte Corporation
Treatment for: Cholangiocarcinoma
Pemazyre (pemigatinib) is a selective fibroblast growth factor receptor (FGFR) inhibitor for the treatment of locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements, as detected by an FDA-approved test.
FDA Approves Pemazyre (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma
Emerphed (ephedrine sulfate) Injection
Date of Approval: April 17, 2020
Company: Nexus Pharmaceuticals, Inc.
Treatment for: Hypotension
Emerphed (ephedrine sulfate) is a ready-to-use formulation of the approved pressor agent ephedrine indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
FDA Approves Emerphed (ephedrine sulfate) Ready-to-Use Injection for Hypotension During Anesthesia
Trodelvy (sacituzumab govitecan-hziy) Injection
Date of Approval: April 22, 2020
Company: Immunomedics, Inc.
Treatment for: Breast Cancer
Trodelvy (sacituzumab govitecan-hziy) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate for the treatment of patients with previously-treated metastatic triple-negative breast cancer (mTNBC).
FDA Approves Trodelvy (sacituzumab govitecan-hziy) for Previously-Treated Metastatic Triple Negative Breast Cancer
MenQuadfi (meningococcal (groups A, C, Y, W) conjugate vaccine) Injection
Date of Approval: April 23, 2020
Company: Sanofi
Treatment for: Meningococcal Meningitis Prophylaxis
MenQuadfi (meningococcal (groups A, C, Y, W) conjugate vaccine) is a MenACWY vaccine indicated for active immunization for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 2 years of age and older.
FDA Approves MenQuadfi (Meningococcal (Groups A, C, Y, W) Conjugate Vaccine) for Meningococcal (MenACWY) Vaccination
Ongentys (opicapone) Capsules
Date of Approval: April 24, 2020
Company: Neurocrine Biosciences, Inc.
Treatment for: Parkinson's Disease
Ongentys (opicapone) is a catechol-O-methyltransferase (COMT) inhibitor indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.
FDA Approves Ongentys (opicapone) as an Add-On Treatment for Patients with Parkinson’s Disease Experiencing “Off” Episodes
Darzalex Faspro (daratumumab and hyaluronidase-fihj) Injection
Date of Approval: May 1, 2020
Company: The Janssen Pharmaceutical Companies of Johnson & Johnson
Treatment for: Multiple Myeloma
Darzalex Faspro (daratumumab and hyaluronidase-fihj) is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase indicated for the treatment of adult patients with multiple myeloma.
FDA Approves Darzalex Faspro (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Multiple Myeloma
Fensolvi (leuprolide acetate) Injection
Date of Approval: May 1, 2020
Company: Tolmar Pharmaceuticals, Inc.
Treatment for: Precocious Puberty
Fensolvi (leuprolide acetate) is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty.
FDA Approves Fensolvi (leuprolide acetate) for Injectable Suspension for Pediatric Patients with Central Precocious Puberty
Elyxyb (celecoxib) Oral Solution
Date of Approval: May 5, 2020
Company: Dr. Reddy’s Laboratories Limited
Treatment for: Migraine
Elyxyb (celecoxib) is an oral solution formulation of the nonsteroidal anti-inflammatory drug celecoxib (first approved under the brand name Celebrex) indicated for the acute treatment of migraine with or without aura in adults.
FDA Approves Elyxyb (celecoxib) Oral Solution For Acute Treatment Of Migraine With Or Without Aura In Adults
Darzalex Faspro (daratumumab and hyaluronidase-fihj) Injection
Date of Approval: May 1, 2020
Company: The Janssen Pharmaceutical Companies of Johnson & Johnson
Treatment for: Multiple Myeloma
Darzalex Faspro (daratumumab and hyaluronidase-fihj) is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase indicated for the treatment of adult patients with multiple myeloma.
FDA Approves Darzalex Faspro (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Multiple Myeloma
Fensolvi (leuprolide acetate) Injection
Date of Approval: May 1, 2020
Company: Tolmar Pharmaceuticals, Inc.
Treatment for: Precocious Puberty
Fensolvi (leuprolide acetate) is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty.
Elyxyb (celecoxib) Oral Solution
Date of Approval: May 5, 2020
Company: Dr. Reddy’s Laboratories Limited
Treatment for: Migraine
Elyxyb (celecoxib) is an oral solution formulation of the nonsteroidal anti-inflammatory drug celecoxib (first approved under the brand name Celebrex) indicated for the acute treatment of migraine with or without aura in adults.
FDA Approves Elyxyb (celecoxib) Oral Solution For Acute Treatment Of Migraine With Or Without Aura In Adults
Tabrecta (capmatinib) Tablets
Date of Approval: May 6, 2020
Company: Novartis
Treatment for: Non-Small Cell Lung Cancer
Tabrecta (capmatinib) is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
FDA Approves Tabrecta (capmatinib) for Metastatic Non-Small Cell Lung Cancer with METex14
Retevmo (selpercatinib) Capsules
Date of Approval: May 8, 2020
Company: Eli Lilly and Company
Treatment for: Non-Small Cell Lung Cancer, Thyroid Cancer
Retevmo (selpercatinib) is a kinase inhibitor for the treatment of patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer.
FDA Approves Retevmo (selpercatinib) for Patients with Advanced RET-Driven Lung and Thyroid Cancers
Qinlock (ripretinib) Tablets
Date of Approval: May 15, 2020
Company: Deciphera Pharmaceuticals, Inc.
Treatment for: Gastrointestinal Stromal Tumor
Qinlock (ripretinib) is a broad-spectrum KIT and PDGFRα inhibitor for the treatment of patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
FDA Approves Qinlock (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Kynmobi (apomorphine hydrochloride) Sublingual Film
Date of Approval: May 21, 2020
Company: Sunovion Pharmaceuticals Inc.
Treatment for: Parkinson's Disease
Kynmobi (apomorphine sublingual film) is a novel formulation of the approved dopamine agonist apomorphine for the on-demand management of OFF episodes associated with Parkinson’s disease (PD).
FDA Approves Kynmobi (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson’s Disease OFF Episodes
Phexxi (lactic acid, citric acid and potassium bitartrate) Vaginal Gel - formerly Amphora
Date of Approval: May 22, 2020
Company: Evofem, Inc.
Treatment for: Contraception
Phexxi (lactic acid, citric acid and potassium bitartrate) is a non-hormonal vaginal gel indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.
FDA Approves Phexxi (lactic acid, citric acid and potassium bitartrate) Non-Hormonal Prescription Gel for the Prevention of Pregnancy
(artesunate) for Injection
Date of Approval: May 26, 2020
Company: Amivas (US), LLC
Treatment for: Malaria
Artesunate for Injection is an antimalarial indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.
FDA Approves Artesunate for Injection for the Treatment of Severe Malaria
Cardiology/Vascular Diseases
Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) ; FoldRx Pharmaceuticals; For the treatment of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis, Approved May 2019
Dermatology
Duobrii (halobetasol propionate and tazarotene) ; Ortho Dermatologics; For the treatment of plaque psoriasis , Approved April 2019
Jeuveau (prabotulinumtoxinA-xvfs); Evolus; For the improvement of glabellar lines, Approved February 2019
Skyrizi (risankizumab-rzaa) ; AbbVie; For the treatment of plaque psoriasis, Approved April 2019
Endocrinology
Jatenzo (testosterone undecanoate); Clarus Therapeutics; For the treatment of male conditions associated with a deficiency or absence of endogenous testosterone , Approved March 2019
Family Medicine
Tosymra (sumatriptan) nasal spray; Dr. Reddy's Labs; For the treatment of acute migraine in adults, Approved January 2019
Genetic Disease
Esperoct [antihemophilic factor (recombinant), glycopegylated-exei]; Novo Nordisk; For the treatment of hemophilia A, Approved February 2019
Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) ; FoldRx Pharmaceuticals; For the treatment of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis, Approved May 2019
Zolgensma (onasemnogene abeparvovec-xioi) ; Avexis; For the treatment of pediatrics. 2 years of age with spinal muscular atrophy with bi-allelic mutations in the SMN1 gene, Approved May 2019
Hematology
Cablivi (caplacizumab-yhdp); Ablynx; For the treatment of acquired thrombotic thrombocytopenic purpura, Approved February 2019
Esperoct [antihemophilic factor (recombinant), glycopegylated-exei]; Novo Nordisk; For the treatment of hemophilia A, Approved February 2019
Venclexta (venetoclax) plus Gazyva (obinutuzumab); Genentech and AbbVie; For the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma , Approved May 2019
Hepatology (Liver, Pancreatic, Gall Bladder)
Cyramza (ramucirumab) ; Eli Lilly; For the treatment of hepatocellular carcinoma with elevated alpha-fetoprotein (AFP), Approved May 2019
Egaten (triclabendazole); Novartis; For the treatment of fascioliasis (liver fluke infestation), Approved February 2019
Immunology
Asceniv (Immune Globulin Intravenous, Human – slra 10% Liquid); ADMA Biologics; For the treatment of Primary Humoral Immunodeficiency Disease , Approved April 2019
Dovato (dolutegravir and lamivudine) ; ViiV Healthcare; For the treatment of HIV-1 infection in adults, Approved April 2019
Ruzurgi (amifampridine); Jacobus Pharmaceuticals; For the treatment of Lambert-Eaton myasthenic syndrome in pediatrics, Approved May 2019
Infections and Infectious Diseases
Dengvaxia (Dengue Tetravalent Vaccine, Live) ; sanofi pasteur; For the prevention of dengue disease, Approved May 2019
Dovato (dolutegravir and lamivudine) ; ViiV Healthcare; For the treatment of HIV-1 infection in adults, Approved April 2019
Egaten (triclabendazole); Novartis; For the treatment of fascioliasis (liver fluke infestation), Approved February 2019
Jakafi (ruxolitinib); Incyte; For the treatment of steroid-refractory acute graft-versus-host disease in adults and pediatrics >12 years , Approved May 2019
Musculoskeletal
Cimzia (certolizumab pegol); UCB; For the treatment of non-radiographic axial spondyloarthritis, Approved March 2019
Evenity (romosozumab-aqqg); Amgen; For the treatment of osteoporosis in postmenopausal women at high risk for fracture, Approved April 2019
Mavenclad (cladribine) ; Merck; For the treatment of relapsing multiple sclerosis, Approved March 2019
Mayzent (siponimod); Novartis; For the treatment of relapsing multiple sclerosis, Approved March 2019
Ruzurgi (amifampridine); Jacobus Pharmaceuticals; For the treatment of Lambert-Eaton myasthenic syndrome in pediatrics, Approved May 2019
Zolgensma (onasemnogene abeparvovec-xioi) ; Avexis; For the treatment of pediatrics. 2 years of age with spinal muscular atrophy with bi-allelic mutations in the SMN1 gene, Approved May 2019
Nephrology
Bavencio (avelumab) plus Inlyta (axitinib) ; Merck and Pfizer; For the first line treatment of advanced renal cell carcinoma, Approved May 2019
Keytruda (pembrolizumab); Merck; For the treatment of advanced renal cell carcinoma, Approved April 2019
Neurology
Mavenclad (cladribine) ; Merck; For the treatment of relapsing multiple sclerosis, Approved March 2019
Mayzent (siponimod); Novartis; For the treatment of relapsing multiple sclerosis, Approved March 2019
Nayzilam (midazolam); UCB; For the treatment of intermittent, stereotypic episodes of frequent seizure activity, Approved May 2019
Ruzurgi (amifampridine); Jacobus Pharmaceuticals; For the treatment of Lambert-Eaton myasthenic syndrome in pediatrics, Approved May 2019
Spravato (esketamine) nasal spray; Janssen Pharmaceuticals; For the treatment of treatment-resistant depression in adults, Approved March 2019
Sunosi (solriamfetol) ; Jazz Pharmaceuticals; For the treatment of excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea, Approved March 2019
Tosymra (sumatriptan) nasal spray; Dr. Reddy's Labs; For the treatment of acute migraine in adults, Approved January 2019
Obstetrics/Gynecology (Women’s Health)
Evenity (romosozumab-aqqg); Amgen; For the treatment of osteoporosis in postmenopausal women at high risk for fracture, Approved April 2019
Herceptin Hylecta (trastuzumab and hyaluronidase-oysk); Halozyme; For the treatment of HER2-overexpressing breast cancer, Approved February 2019
Piqray (alpelisib) ; Novartis; For the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer, Approved May 2019
Tecentriq (atezolizumab); Genentech/Roche; For the treatment of triple negative breast cancer, Approved March 2019
Zulresso (brexanolone); Sage Therapeutics; For the treatment of postpartum depression, Approved March 2019
Oncology
Balversa (erdafitinib); Janssen Oncology; For the treatment of locally advanced or metastatic urothelial carcinoma , Approved April 2019
Bavencio (avelumab) plus Inlyta (axitinib) ; Merck and Pfizer; For the first line treatment of advanced renal cell carcinoma, Approved May 2019
Cyramza (ramucirumab) ; Eli Lilly; For the treatment of hepatocellular carcinoma with elevated alpha-fetoprotein (AFP), Approved May 2019
Herceptin Hylecta (trastuzumab and hyaluronidase-oysk); Halozyme; For the treatment of HER2-overexpressing breast cancer, Approved February 2019
Keytruda (pembrolizumab); Merck; For the treatment of advanced renal cell carcinoma, Approved April 2019
Keytruda (pembrolizumab); Merck; For the treatment of stage III non-small cell lung cancer, Approved April 2019
Piqray (alpelisib) ; Novartis; For the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer, Approved May 2019
Tecentriq (atezolizumab); Genentech/Roche; For the treatment of extensive-stage small cell lung cancer , Approved March 2019
Tecentriq (atezolizumab); Genentech/Roche; For the treatment of triple negative breast cancer, Approved March 2019
Venclexta (venetoclax) plus Gazyva (obinutuzumab); Genentech and AbbVie; For the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma , Approved May 2019
Ophthalmology
Rocklatan (netarsudil and latanoprost ophthalmic solution); Aerie Pharmaceuticals; For the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Approved March 2019
Pediatrics/Neonatology
Nayzilam (midazolam); UCB; For the treatment of intermittent, stereotypic episodes of frequent seizure activity, Approved May 2019
Ruzurgi (amifampridine); Jacobus Pharmaceuticals; For the treatment of Lambert-Eaton myasthenic syndrome in pediatrics, Approved May 2019
Zolgensma (onasemnogene abeparvovec-xioi) ; Avexis; For the treatment of pediatrics
Psychiatry/Psychology
Spravato (esketamine) nasal spray; Janssen Pharmaceuticals; For the treatment of treatment-resistant depression in adults, Approved March 2019
Zulresso (brexanolone); Sage Therapeutics; For the treatment of postpartum depression, Approved March 2019
Pulmonary/Respiratory Diseases
Duaklir Pressair (aclidinium bromide and formoterol fumarate) ; Circassia Pharmaceuticals; For the maintenance treatment of chronic obstructive pulmonary disease, Approved April 2019
Keytruda (pembrolizumab); Merck; For the treatment of stage III non-small cell lung cancer, Approved April 2019
Sunosi (solriamfetol); Jazz Pharmaceuticals; For the treatment of excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea, Approved March 2019
Tecentriq (atezolizumab); Genentech/Roche; For the treatment of extensive-stage small cell lung cancer , Approved March 2019
Rheumatology
Cimzia (certolizumab pegol); UCB; For the treatment of non-radiographic axial spondyloarthritis, Approved March 2019
Urology
Balversa (erdafitinib); Janssen Oncology; For the treatment of locally advanced or metastatic urothelial carcinoma , Approved April 2019
Jatenzo (testosterone undecanoate); Clarus Therapeutics; For the treatment of male conditions associated with a deficiency or absence of endogenous testosterone , Approved March 2019
Vaccines
Dengvaxia (Dengue Tetravalent Vaccine, Live) ; sanofi pasteur; For the prevention of dengue disease, Approved May 2019
Gastroenterology
Lutathera (lutetium Lu 177 dotatate); Advanced Accelerator Applications; For the treatment of gastroenteropancreatic neuroendocrine tumors, Approved January 2018
Infections and Infectious Diseases
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide); Gilead; For the treatment of HIV-1 infection in adults, Approved February 2018
Oncology
Erleada (apalutamide); Janssen Oncology; For the treatment of prostate cancer, Approved February 2018
Lutathera (lutetium Lu 177 dotatate); Advanced Accelerator Applications; For the treatment of gastroenteropancreatic neuroendocrine tumors, Approved January 2018
Pulmonary/Respiratory Diseases
Symdeko (tezacaftor/ivacaftor) ; Vertex; For the treatment of cystic fibrosis , Approved February 2018
Urology
Erleada (apalutamide); Janssen Oncology; For the treatment of prostate cancer, Approved February 2018
Cardiology/Vascular Diseases
Bevyxxa (betrixaban); Portola Pharmaceuticals; For the the prophylaxis of venous thromboembolism, Approved June 2017
Dermatology
Bavencio (avelumab) ; EMD Serono/Pfizer; For the treatment of Merkel cell carcinoma , Approved March 2017
Baxdela (delafloxacin) tablets and injection; Melinta Therapeutics; For the treatment of acute bacterial skin and skin structure infections, Approved June 2017
Dupixent (dupilumab); Regeneron Pharmaceuticals; For the treatment of atopic dermatitis, Approved March 2017
Eskata (hydrogen peroxide); Aclaris Therapeutics; For the treatment of seborrheic keratoses, Approved December 2017
Rhofade (oxymetazoline hydrochloride); Allergan; For the treatment of facial erythema associated with rosacea, Approved January 2017
Siliq (brodalumab); Valeant Pharmaceuticals; For the treatment of plaque psoriasis , Approved February 2017
Tremfya (guselkumab); Janssen Biotech; For the treatment of moderate-to-severe plaque psoriasis, Approved July 2017
Xepi (ozenoxacin) ; Medimetriks; For the treatment of impetigo, Approved December 2017
Endocrinology
Macrilen (macimorelin); Stonebridge Biopharma; For the diagnosis of adult growth hormone deficiency , Approved December 2017
Ozempic (semaglutide); Novo Nordisk; For the treatment of type II diabetes, Approved December 2017
Parsabiv (etelcalcetide); Amgen; For the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis, Approved February 2017
Qtern (dapagliflozin and saxagliptin) ; AstraZeneca; For the treatment of inadequately controlled type II diabetes , Approved February 2017
Steglatro (ertugliflozin); Merck; For the treatment of type 2 diabetes mellitus, Approved December 2017
Family Medicine
Ozempic (semaglutide); Novo Nordisk; For the treatment of type II diabetes, Approved December 2017
Qtern (dapagliflozin and saxagliptin) ; AstraZeneca; For the treatment of inadequately controlled type II diabetes , Approved February 2017
Steglatro (ertugliflozin); Merck; For the treatment of type 2 diabetes mellitus, Approved December 2017
Trulance (plecanatide); Synergy Pharmaceuticals; For the treatment of adults with chronic idiopathic constipation, Approved January 2017
Gastroenterology
Symproic (naldemedine); Shionogi; For the treatment of opioid-induced constipation, Approved March 2017
Trulance (plecanatide); Synergy Pharmaceuticals; For the treatment of adults with chronic idiopathic constipation, Approved January 2017
Xermelo (telotristat ethyl); Lexicon Pharmaceuticals; For the treatment of carcinoid syndrome diarrhea, Approved February 2017
Genetic Disease
Haegarda (C1 Esterase Inhibitor Subcutaneous [Human]) ; CSL Behring; For the routine prophylaxis to prevent Hereditary Angioedema attacks, Approved June 2017
Brineura (cerliponase alfa); BioMarin; For the treatment of late infantile neuronal ceroid lipofuscinosis type 2 , Approved April 2017
Mepsevii (vestronidase alfa-vjbk) ; Ultragenyx; For the treatment of Mucopolysaccharidosis VII , Approved November 2017
Hematology
Aliqopa (copanlisib); Bayer; For the treatment of follicular lymphoma , Approved September 2017
Besponsa (inotuzumab ozogamicin); Pfizer; For the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, Approved August 2017
Calquence (acalabrutinib); Acerta Pharmaceuticals; For the treatment of mantle cell lymphoma , Approved November 2017
Endari (L-glutamine oral powder); Emmaus Life Sciences; For the treatment of sickle cell disease , Approved July 2017
Giapreza (angiotensin II) ; La Jolla Pharmaceuticals; For the treatment of septic shock, Approved December 2017
Hemlibra (emicizumab-kxwh); Genentech; For the prevention or reduction of bleeding episodes in patients with hemophilia A , Approved November 2017
IDHIFA (enasidenib); Celgene; For the treatment of relapsed or refractory acute myeloid leukemia with IDH2 mutation , Approved August 2017
Kymriah (tisagenlecleucel); Novartis; For the treatment of refractory B-cell precursor acute lymphoblastic leukemia , Approved August 2017
Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) ; Novo Nordisk; For the treatment of hemophilia B, Approved June 2017
Rydapt (midostaurin); Novartis; For the treatment of FLT3 positive acute myeloid leukemia and mastocytosis , Approved April 2017
Vyxeos (daunorubicin and cytarabine) ; Jazz Pharma; For the treatment of newly-diagnosed therapy-related AML or AML with myelodysplasia-related changes, Approved August 2017
Yescarta (axicabtagene ciloleucel); Kite Pharmaceuticals; For the treatment of relapsed or refractory large B-cell lymphomas, Approved October 2017
Hepatology (Liver, Pancreatic, Gall Bladder)
Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] ; Dynavax; For the prevention of hepatitis B virus infection, Approved November 2017
Mavyret (glecaprevir and pibrentasvir) ; AbbVie; For the treatment of chronic HCV genotype 1, 2, 3, 4, 5 or 6, Approved August 2017
Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) ; Gilead; For the treatment of hepatitis C, Approved July 2017
Immunology
Haegarda (C1 Esterase Inhibitor Subcutaneous [Human]) ; CSL Behring; For the routine prophylaxis to prevent Hereditary Angioedema attacks, Approved June 2017
Actemra (tocilizumab) injection; Genentech; For the treatment of CAR T cell-induced severe or life-threatening cytokine release syndrome, Approved September 2017
Ocrevus (ocrelizumab); Genentech; For the treatment of multiple sclerosis, Approved March 2017
Tremfya (guselkumab); Janssen Biotech; For the treatment of moderate-to-severe plaque psoriasis, Approved July 2017
Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) ; Gilead; For the treatment of hepatitis C, Approved July 2017
Zerviate (cetirizine ophthalmic solution 0.24%); NicOx; For the treatment of ocular itching associated with allergic conjunctivitis, Approved May 2017
Infections and Infectious Diseases
Baxdela (delafloxacin) tablets and injection; Melinta Therapeutics; For the treatment of acute bacterial skin and skin structure infections, Approved June 2017
Benznidazole; Chemo Group; For the treatment of Chagas disease , Approved August 2017
Giapreza (angiotensin II) ; La Jolla Pharmaceuticals; For the treatment of septic shock, Approved December 2017
Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] ; Dynavax; For the prevention of hepatitis B virus infection, Approved November 2017
Juluca (dolutegravir and rilpivirine); ViiV Healthcare; For the treatment of HIV-1 infection in adults, Approved November 2017
KedRab [Rabies Immune Globulin (Human)]; Kedrion Biopharma ; For the post-exposure prophylaxis of rabies infection, Approved August 2017
Mavyret (glecaprevir and pibrentasvir) ; AbbVie; For the treatment of chronic HCV genotype 1, 2, 3, 4, 5 or 6, Approved August 2017
Prevymis (letermovir) ; Merck; For the prevention of cytomegalovirus following allogenic hematopoietic stem cell transplant, Approved November 2017
Shingrix (Zoster Vaccine Recombinant, Adjuvanted) ; GlaxoSmithKline; For the prevention of herpes zoster (shingles), Approved October 2017
Solosec (secnidazole) ; Symbiomix Therapeutics; For the treatment of bacterial vaginosis , Approved September 2017
Vabomere (meropenem and vaborbactam); The Medicines Company; For the treatment of complicated urinary tract infections , Approved August 2017
Xepi (ozenoxacin) ; Medimetriks; For the treatment of impetigo, Approved December 2017
Internal Medicine
Duzallo (lesinurad and allopurinol) ; Ardea Biosciences; For the treatment of hyperuricemia associated with gout , Approved August 2017
Musculoskeletal
Brineura (cerliponase alfa); BioMarin; For the treatment of late infantile neuronal ceroid lipofuscinosis type 2 , Approved April 2017
Duzallo (lesinurad and allopurinol) ; Ardea Biosciences; For the treatment of hyperuricemia associated with gout , Approved August 2017
Emflaza (deflazacort); Marathon Pharmaceuticals; For the treatment of Duchenne muscular dystrophy, Approved February 2017
Kevzara (sarilumab); Sanofi ; For the treatment of active rheumatoid arthritis, Approved May 2017
Ocrevus (ocrelizumab); Genentech; For the treatment of multiple sclerosis, Approved March 2017
Tymlos (abaloparatide) ; Radius Health; For the treatment of postmenopausal women with osteoporosis at high risk for fracture, Approved April 2017
Zilretta (triamcinolone acetonide extended-release injectable suspension); Flexion Therapeutics; For the treatment of osteoarthritis knee pain, Approved October 2017
Nephrology
Parsabiv (etelcalcetide); Amgen; For the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis, Approved February 2017
Neurology
Austedo (deutetrabenazine) ; Teva Pharmaceuticals; For the treatment of chorea associated with Huntington’s disease and tardive dyskinesia , Initial approval April 2017
Brineura (cerliponase alfa); BioMarin; For the treatment of late infantile neuronal ceroid lipofuscinosis type 2 , Approved April 2017
Gocovri (amantadine) ; Adamas Pharmaceuticals; For the treatment of Parkinson's disease dyskinesia, Approved August 2017
Ingrezza (valbenazine); Neurocrine Biosciences; For the treatment of tardive dyskinesia, Approved April 2017
Radicava (edaravone); Mitsubishi Tanabe Pharma; For the treatment of amyotrophic lateral sclerosis , Approved May 2017
Xadago (safinamide); Newron Pharmaceuticals; For the treatment of Parkinson's disease, Approved March 2017
Obstetrics/Gynecology (Women’s Health)
Kisqali (ribociclib); Novartis; For the treatment of breast cancer, Approved March 2017
Solosec (secnidazole) ; Symbiomix Therapeutics; For the treatment of bacterial vaginosis , Approved September 2017
Tymlos (abaloparatide) ; Radius Health; For the treatment of postmenopausal women with osteoporosis at high risk for fracture, Approved April 2017
Verzenio (abemaciclib); Eli Lilly; For the treatment of HR+, HER2- breast cancer, Approved September 2017
Zejula (niraparib); Tesaro; For the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer , Approved March 2017
Oncology
Aliqopa (copanlisib); Bayer; For the treatment of follicular lymphoma , Approved September 2017
Alunbrig (brigatinib); Ariad Pharmaceuticals; For the treatment of advanced ALK-positive metastatic non-small cell lung cancer, Approved April 2017
Bavencio (avelumab) ; EMD Serono/Pfizer; For the treatment of Merkel cell carcinoma , Approved March 2017
Besponsa (inotuzumab ozogamicin); Pfizer; For the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, Approved August 2017
Calquence (acalabrutinib); Acerta Pharmaceuticals; For the treatment of mantle cell lymphoma , Approved November 2017
IDHIFA (enasidenib); Celgene; For the treatment of relapsed or refractory acute myeloid leukemia with IDH2 mutation , Approved August 2017
Imfinzi (durvalumab); AstraZeneca; For the treatment of advanced or metastatic urothelial carcinoma and Stage III non-small cell lung cancer, Initially approved May 2017
Kisqali (ribociclib); Novartis; For the treatment of breast cancer, Approved March 2017
Kymriah (tisagenlecleucel); Novartis; For the treatment of refractory B-cell precursor acute lymphoblastic leukemia , Approved August 2017
Nerlynx (neratinib); Puma Biotech; For the treatment of HER2 breast cancer, Approved July 2017
Rydapt (midostaurin); Novartis; For the treatment of FLT3 positive acute myeloid leukemia and mastocytosis , Approved April 2017
Verzenio (abemaciclib); Eli Lilly; For the treatment of HR+, HER2- breast cancer, Approved September 2017
Vyxeos (daunorubicin and cytarabine) ; Jazz Pharma; For the treatment of newly-diagnosed therapy-related AML or AML with myelodysplasia-related changes, Approved August 2017
Xermelo (telotristat ethyl); Lexicon Pharmaceuticals; For the treatment of carcinoid syndrome diarrhea, Approved February 2017
Yescarta (axicabtagene ciloleucel); Kite Pharmaceuticals; For the treatment of relapsed or refractory large B-cell lymphomas, Approved October 2017
Zejula (niraparib); Tesaro; For the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer , Approved March 2017
Ophthalmology
Luxturna (voretigene neparvovec); Spark Therapeutics; For the treatment of vision loss due to confirmed biallelic RPE65-mediated inherited retinal disease, Approved December 2017
Rhopressa (netarsudil ophthalmic solution) ; Aerie Pharmaceuticals; For the treatment of glaucoma or ocular hypertension, Approved December 2017
Vyzulta (latanoprostene bunod ophthalmic solution); Bausch & Lomb; For the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Approved November 2017
Zerviate (cetirizine ophthalmic solution 0.24%); NicOx; For the treatment of ocular itching associated with allergic conjunctivitis, Approved May 2017
Pediatrics/Neonatology
Brineura (cerliponase alfa); BioMarin; For the treatment of late infantile neuronal ceroid lipofuscinosis type 2 , Approved April 2017
Emflaza (deflazacort); Marathon Pharmaceuticals; For the treatment of Duchenne muscular dystrophy, Approved February 2017
Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) ; Novo Nordisk; For the treatment of hemophilia B, Approved June 2017
Pharmacology/Toxicology
Actemra (tocilizumab) injection; Genentech; For the treatment of CAR T cell-induced severe or life-threatening cytokine release syndrome, Approved September 2017
Gocovri (amantadine) ; Adamas Pharmaceuticals; For the treatment of Parkinson's disease dyskinesia, Approved August 2017
Pulmonary/Respiratory Diseases
Imfinzi (durvalumab); AstraZeneca; For the treatment of advanced or metastatic urothelial carcinoma and Stage III non-small cell lung cancer, Initially approved May 2017
Rheumatology
Duzallo (lesinurad and allopurinol) ; Ardea Biosciences; For the treatment of hyperuricemia associated with gout , Approved August 2017
Kevzara (sarilumab); Sanofi ; For the treatment of active rheumatoid arthritis, Approved May 2017
Zilretta (triamcinolone acetonide extended-release injectable suspension); Flexion Therapeutics; For the treatment of osteoarthritis knee pain, Approved October 2017
Urology
Imfinzi (durvalumab); AstraZeneca; For the treatment of advanced or metastatic urothelial carcinoma and Stage III non-small cell lung cancer, Initially approved May 2017
Vabomere (meropenem and vaborbactam); The Medicines Company; For the treatment of complicated urinary tract infections , Approved August 2017
Vaccines
Shingrix (Zoster Vaccine Recombinant, Adjuvanted) ; GlaxoSmithKline; For the prevention of herpes zoster (shingles), Approved October 2017
Cardiology/Vascular Diseases
Byvalson (nebivolol and valsartan); Allergan; For the treatment of hypertension, Approved June 2016
Yosprala (aspirin and omeprazole); Aralez Pharmaceuticals; For the prevention of cardiovascular and cerebrovascular events, Approved September 2016
Dermatology
Ameluz (aminolevulinic acid hydrochloride); Biofrontera Pharma; For the treatment of actinic keratoses, Approved May 2016
Eucrisa (crisaborole) ointment; Pfizer; For the treatment of atopic dermatitis, Approved December 2016
Taltz (ixekizumab); Eli Lilly; For the treatment of plaque psoriasis and active psoriatic arthritis, Approved March 2016
Endocrinology
Adlyxin (lixisenatide); Sanofi Aventis; For the treatment of type II diabetes, Approved July 2016
Soliqua 100/33 (insulin glargine and lixisenatide injection); Sanofi Aventis; For the treatment of inadequately controlled type II diabetes, Approved November 2016
Xultophy 100/3.6 (insulin degludec and liraglutide injection); Novo Nordisk; For the treatment of inadequately controlled type II diabetes, Approved November 2016
Family Medicine
Byvalson (nebivolol and valsartan); Allergan; For the treatment of hypertension, Approved June 2016
Onzetra Xsail (sumatriptan nasal powder) ; Avanir; For the treatment of migraine, Approved January 2016
Soliqua 100/33 (insulin glargine and lixisenatide injection); Sanofi Aventis; For the treatment of inadequately controlled type II diabetes, Approved November 2016
Xultophy 100/3.6 (insulin degludec and liraglutide injection); Novo Nordisk; For the treatment of inadequately controlled type II diabetes, Approved November 2016
Gastroenterology
Zinplava (bezlotoxumab); Merck; For the treatment of recurrent Clostridium difficile infection in patients receiving antibacterial treatment, Approved October 2016
Genetic Disease
Spinraza (nusinersen); Biogen; For the treatment of spinal muscular atrophy, Approved December 2016
Hematology
Afstyla (Antihemophilic Factor (Recombinant), Single Chain); CSL Behring; For the treatment of hemophillia A, Approved May 2016
Idelvion (Coagulation Factor IX (Recombinant), Albumin Fusion Protein); CSL Behring; For the treatment of hemophilia B, Approved March 2016
Kovaltry [Antihemophilic Factor (Recombinant)]; Bayer ; For the treatment of hemophillia A, Approved March 2016
Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of classical Hodgkin lymphoma, Approved May 2016
Venclexta (venetoclax); AbbVie; For the treatment of chronic lymphocytic leukemia with 17p deletion, Approved April 2016
Hepatology (Liver, Pancreatic, Gall Bladder)
Defitelio (defibrotide sodium); Jazz Pharmaceuticals; For the treatment of hepatic veno-occlusive disease with renal or pulmonary dysfunction following HSCT, Approved March 2016
Ocaliva (obeticholic acid); Intercept Pharmaceuticals; For the treatment of primary biliary cholangitis, Approved May 2016
Vemlidy (tenofovir alafenamide); Gilead Sciences; For the treatment of chronic hepatitis B , Approved November 2016
Zepatier (elbasvir and grazoprevir); Merck; For the treatment of chronic HCV genotypes 1 or 4 , Approved January 2016
Immunology
Afstyla (Antihemophilic Factor (Recombinant), Single Chain); CSL Behring; For the treatment of hemophillia A, Approved May 2016
Descovy (emtricitabine and tenofovir alafenamide); Gilead; For the treatment of HIV-1 infection, Approved April 2016
Epclusa (sofosbuvir and velpatasvir) ; Gilead Sciences; For the treatment of hepatitis C, Approved June 2016
Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide); Gilead Sciences; For the treatment of HIV-1 as initial therapy, Approved March 2016
Taltz (ixekizumab); Eli Lilly; For the treatment of plaque psoriasis and active psoriatic arthritis, Approved March 2016
Vaxchora (Cholera Vaccine, Live, Oral); PaxVax; For active immunization against Cholera, Approved June 2016
Infections and Infectious Diseases
Anthim (obiltoxaximab); Elusys Therapeutics; For the treatment of inhalational anthrax , Approved March 2016
Descovy (emtricitabine and tenofovir alafenamide); Gilead; For the treatment of HIV-1 infection, Approved April 2016
Epclusa (sofosbuvir and velpatasvir) ; Gilead Sciences; For the treatment of hepatitis C, Approved June 2016
Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide); Gilead Sciences; For the treatment of HIV-1 as initial therapy, Approved March 2016
Syndros (dronabinol oral solution); Insys Therapeutics; For the treatment of anorexia associated with AIDS and nausea and vomiting associated with cancer chemotherapy, Approved July 2016
Vaxchora (Cholera Vaccine, Live, Oral); PaxVax; For active immunization against Cholera, Approved June 2016
Vemlidy (tenofovir alafenamide); Gilead Sciences; For the treatment of chronic hepatitis B , Approved November 2016
Zepatier (elbasvir and grazoprevir); Merck; For the treatment of chronic HCV genotypes 1 or 4 , Approved January 2016
Zinplava (bezlotoxumab); Merck; For the treatment of recurrent Clostridium difficile infection in patients receiving antibacterial treatment, Approved October 2016
Musculoskeletal
Exondys 51 (eteplirsen); Sarepta Therapeutics; For the treatment of Duchenne muscular dystrophy with mutated DMD gene amenable to exon 51 skipping, Approved September 2016
Spinraza (nusinersen); Biogen; For the treatment of spinal muscular atrophy, Approved December 2016
Zinbryta (daclizumab) ; Biogen; For the treatment of relapsing multiple sclerosis, Approved May 2016
Nephrology
Cabometyx (cabozantinib); Exelixis; For the treatment of advanced renal cell carcinoma, Approved April 2016
Lenvima (lenvatinib); Eisai; For the treatment of advanced renal cell carcinoma, Approved May 2016
Rayaldee (calcifediol) ; Opko Health; For the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, Approved June 2016
Neurology
Briviact (brivaracetam); UCB; For the treatment of partial onset seizures related to epilepsy, Approved February 2016
Carnexiv (carbamazepine); Lundbeck; replacement therapy when oral administration is not feasible, in adults with seizures, Approved October 2016
Exondys 51 (eteplirsen); Sarepta Therapeutics; For the treatment of Duchenne muscular dystrophy with mutated DMD gene amenable to exon 51 skipping, Approved September 2016
Nuplazid (pimavanserin); Acadia Pharmaceuticals; For the treatment of hallucinations and delusions associated with Parkinson’s disease, Approved April 2016
Nuplazid (pimavanserin); Acadia Pharmaceuticals; For the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, Approved May 2016
Onzetra Xsail (sumatriptan nasal powder) ; Avanir; For the treatment of migraine, Approved January 2016
Spinraza (nusinersen); Biogen; For the treatment of spinal muscular atrophy, Approved December 2016
Troxyca ER (oxycodone + naltrexone); Pfizer; For the management of severe pain, Approved August 2016
Zinbryta (daclizumab) ; Biogen; For the treatment of relapsing multiple sclerosis, Approved May 2016
Obstetrics/Gynecology (Women’s Health)
Intrarosa (prasterone vaginal insert); Endoceutics; For the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause, Approved November 2016
Rubraca (rucaparib); Clovis Oncology; For the treatment of advanced ovarian cancer in women with deleterious germline or somatic BRCA mutation, Approved December 2016
Oncology
Cabometyx (cabozantinib); Exelixis; For the treatment of advanced renal cell carcinoma, Approved April 2016
Keytruda (pembrolizumab); Merck; For the treatment of head and neck squamous cell cancer , Approved August 2016
Lartruvo (olaratumab) ; Eli Lilly; For the treatment of soft tissue sarcoma, Approved October 2016
Lenvima (lenvatinib); Eisai; For the treatment of advanced renal cell carcinoma, Approved May 2016
Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of classical Hodgkin lymphoma, Approved May 2016
Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck, Approved November 2016
Rubraca (rucaparib); Clovis Oncology; For the treatment of advanced ovarian cancer in women with deleterious germline or somatic BRCA mutation, Approved December 2016
Sustol (granisetron); Heron Therapeutics; For the prevention of chemotherapy-induced nausea and vomiting, Approved August 2016
Syndros (dronabinol oral solution); Insys Therapeutics; For the treatment of anorexia associated with AIDS and nausea and vomiting associated with cancer chemotherapy, Approved July 2016
Tecentriq (atezolizumab); Genentech; For the treatment of urothelial carcinoma and metastatic non-small cell lung cancer, Approved May 2016
Venclexta (venetoclax); AbbVie; For the treatment of chronic lymphocytic leukemia with 17p deletion, Approved April 2016
Ophthalmology
Humira (adalimumab); Abbvie; For the treatment of uveitis, Approved July 2016
Xiidra (lifitegrast); Shire; For the treatment of dry eye disease, Approved July 2016
Pediatrics/Neonatology
Exondys 51 (eteplirsen); Sarepta Therapeutics; For the treatment of Duchenne muscular dystrophy with mutated DMD gene amenable to exon 51 skipping, Approved September 2016
Kovaltry [Antihemophilic Factor (Recombinant)]; Bayer ; For the treatment of hemophillia A, Approved March 2016
Spinraza (nusinersen); Biogen; For the treatment of spinal muscular atrophy, Approved December 2016
Pharmacology/Toxicology
Sustol (granisetron); Heron Therapeutics; For the prevention of chemotherapy-induced nausea and vomiting, Approved August 2016
Psychiatry/Psychology
Nuplazid (pimavanserin); Acadia Pharmaceuticals; For the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, Approved May 2016
Pulmonary/Respiratory Diseases
Bevespi Aerosphere (glycopyrrolate and formoterol fumarate); AstraZeneca; For the treatment of chronic obstructive pulmonary disease, Approved April 2016
Cinqair (reslizumab); Teva Pharmaceuticals; For the treatment of severe asthma, Approved March 2016
Tecentriq (atezolizumab); Genentech; For the treatment of urothelial carcinoma and metastatic non-small cell lung cancer, Approved May 2016
Rheumatology
Taltz (ixekizumab); Eli Lilly; For the treatment of plaque psoriasis and active psoriatic arthritis, Approved March 2016
Urology
Tecentriq (atezolizumab); Genentech; For the treatment of urothelial carcinoma and metastatic non-small cell lung cancer, Approved May 2016
Vaccines
Vaxchora (Cholera Vaccine, Live, Oral); PaxVax; For active immunization against Cholera, Approved June 2016
